OA13042A - Process for preparing a polymorph of rosiglitazonemaleate. - Google Patents
Process for preparing a polymorph of rosiglitazonemaleate. Download PDFInfo
- Publication number
- OA13042A OA13042A OA1200500267A OA1200500267A OA13042A OA 13042 A OA13042 A OA 13042A OA 1200500267 A OA1200500267 A OA 1200500267A OA 1200500267 A OA1200500267 A OA 1200500267A OA 13042 A OA13042 A OA 13042A
- Authority
- OA
- OAPI
- Prior art keywords
- compound
- solvent
- maleate
- mixture
- preparing
- Prior art date
Links
- 229960003271 rosiglitazone maleate Drugs 0.000 title claims abstract description 58
- SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 title claims abstract description 58
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 20
- 229940125904 compound 1 Drugs 0.000 claims abstract description 52
- 238000002425 crystallisation Methods 0.000 claims abstract description 10
- 239000000463 material Substances 0.000 claims abstract description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 51
- 239000002904 solvent Substances 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 44
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 32
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 24
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 24
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 18
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 8
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 claims description 8
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 claims description 7
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 7
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims description 7
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 claims description 7
- 229940043265 methyl isobutyl ketone Drugs 0.000 claims description 7
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- 238000010899 nucleation Methods 0.000 claims description 6
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 5
- 229940011051 isopropyl acetate Drugs 0.000 claims description 5
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 3
- -1 isopropyl acétate Chemical compound 0.000 claims description 2
- SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 3
- QWTDNUCVQCZILF-UHFFFAOYSA-N iso-pentane Natural products CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 claims 2
- 229940075894 denatured ethanol Drugs 0.000 claims 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 abstract description 6
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 52
- 239000007787 solid Substances 0.000 description 39
- 229960004586 rosiglitazone Drugs 0.000 description 26
- 239000000706 filtrate Substances 0.000 description 17
- 238000001914 filtration Methods 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 13
- 229940093499 ethyl acetate Drugs 0.000 description 13
- 235000019439 ethyl acetate Nutrition 0.000 description 13
- 239000011976 maleic acid Substances 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 12
- 238000001816 cooling Methods 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- 238000010992 reflux Methods 0.000 description 10
- 238000010438 heat treatment Methods 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 239000012065 filter cake Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000004566 IR spectroscopy Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000000634 powder X-ray diffraction Methods 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 3
- 239000011928 denatured alcohol Substances 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000004611 spectroscopical analysis Methods 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 238000002050 diffraction method Methods 0.000 description 2
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- BIIBYWQGRFWQKM-JVVROLKMSA-N (2S)-N-[4-(cyclopropylamino)-3,4-dioxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl]-2-[[(E)-3-(2,4-dichlorophenyl)prop-2-enoyl]amino]-4,4-dimethylpentanamide Chemical compound CC(C)(C)C[C@@H](C(NC(C[C@H](CCN1)C1=O)C(C(NC1CC1)=O)=O)=O)NC(/C=C/C(C=CC(Cl)=C1)=C1Cl)=O BIIBYWQGRFWQKM-JVVROLKMSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- WSNKEJIFARPOSQ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(1-benzothiophen-2-ylmethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2=CC3=C(S2)C=CC=C3)C=CC=1 WSNKEJIFARPOSQ-UHFFFAOYSA-N 0.000 description 1
- MTJGVAJYTOXFJH-UHFFFAOYSA-N 3-aminonaphthalene-1,5-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(N)=CC(S(O)(=O)=O)=C21 MTJGVAJYTOXFJH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004533 oil dispersion Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- KMIOJWCYOHBUJS-HAKPAVFJSA-N vorolanib Chemical compound C1N(C(=O)N(C)C)CC[C@@H]1NC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C KMIOJWCYOHBUJS-HAKPAVFJSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0307259.2A GB0307259D0 (en) | 2003-03-28 | 2003-03-28 | Process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA13042A true OA13042A (en) | 2006-11-10 |
Family
ID=9955778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA1200500267A OA13042A (en) | 2003-03-28 | 2004-03-25 | Process for preparing a polymorph of rosiglitazonemaleate. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20070167494A1 (https=) |
| EP (1) | EP1615918A1 (https=) |
| JP (1) | JP2006521340A (https=) |
| KR (1) | KR20050120670A (https=) |
| CN (1) | CN1768057A (https=) |
| AU (2) | AU2004224068A1 (https=) |
| BR (1) | BRPI0408752A (https=) |
| CA (1) | CA2520249A1 (https=) |
| EA (1) | EA009331B1 (https=) |
| EC (1) | ECSP056038A (https=) |
| GB (1) | GB0307259D0 (https=) |
| IS (1) | IS8087A (https=) |
| MA (1) | MA27727A1 (https=) |
| MX (1) | MXPA05010413A (https=) |
| NO (1) | NO20054911L (https=) |
| OA (1) | OA13042A (https=) |
| WO (1) | WO2004085435A1 (https=) |
| ZA (1) | ZA200507100B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020137940A1 (en) | 1997-12-16 | 2002-09-26 | Smithkline Beecham P.L.C. | 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical |
| US20040248945A1 (en) | 1999-04-23 | 2004-12-09 | Smithkline Beecham P.L.C. | Thiazolidinedione derivative and its use as antidiabetic |
| GB2405403A (en) * | 2003-08-29 | 2005-03-02 | Cipla Ltd | Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base |
| ITMI20041537A1 (it) * | 2004-07-28 | 2004-10-28 | Chemi Spa | Nuova forma polimorfa del rosiglitazone maleato |
| CZ298424B6 (cs) * | 2005-05-24 | 2007-09-26 | Zentiva, A. S. | Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel |
| WO2018140092A1 (en) | 2017-01-27 | 2018-08-02 | Obrien Christopher F | Methods for the administration of certain vmat2 inhibitors |
| ES3024958T3 (en) | 2017-09-21 | 2025-06-05 | Neurocrine Biosciences Inc | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
| JP2021502959A (ja) | 2017-10-10 | 2021-02-04 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 特定のｖｍａｔ２インヒビターを投与するための方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9218830D0 (en) * | 1992-09-05 | 1992-10-21 | Smithkline Beecham Plc | Novel compounds |
| GB9723295D0 (en) * | 1997-11-04 | 1998-01-07 | Smithkline Beecham Plc | Novel process |
| UA67844C2 (uk) * | 1999-04-23 | 2004-07-15 | Смітклайн Бічам Плс | Поліморф 5-[4-[2-(n-метил-n-(2-піридил)аміно)етокси]бензил]тіазолідин-2,4-діону солі малеїнової кислоти |
| PL351685A1 (en) * | 1999-04-23 | 2003-06-02 | Smithkline Beecham Plc | Novel pharmaceutical |
| DE60004658T2 (de) * | 1999-04-23 | 2004-06-24 | Smithkline Beecham Plc, Brentford | Thiazolidindionderivat und seine verwendung als antidiabetikum |
| CZ2003864A3 (cs) * | 2000-09-26 | 2004-01-14 | Dr. Reddy´S Research Foundation | Nové polymorfní formy 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl]thiazolidin-2,4-dion-maleátu a způsob jejich přípravy |
-
2003
- 2003-03-28 GB GBGB0307259.2A patent/GB0307259D0/en not_active Ceased
-
2004
- 2004-03-25 KR KR1020057018143A patent/KR20050120670A/ko not_active Withdrawn
- 2004-03-25 BR BRPI0408752-6A patent/BRPI0408752A/pt not_active IP Right Cessation
- 2004-03-25 OA OA1200500267A patent/OA13042A/en unknown
- 2004-03-25 WO PCT/GB2004/001306 patent/WO2004085435A1/en not_active Ceased
- 2004-03-25 CA CA002520249A patent/CA2520249A1/en not_active Abandoned
- 2004-03-25 US US10/551,021 patent/US20070167494A1/en not_active Abandoned
- 2004-03-25 EP EP04723254A patent/EP1615918A1/en not_active Withdrawn
- 2004-03-25 CN CNA2004800083916A patent/CN1768057A/zh active Pending
- 2004-03-25 AU AU2004224068A patent/AU2004224068A1/en not_active Abandoned
- 2004-03-25 EA EA200501527A patent/EA009331B1/ru unknown
- 2004-03-25 MX MXPA05010413A patent/MXPA05010413A/es unknown
- 2004-03-25 JP JP2006506028A patent/JP2006521340A/ja not_active Withdrawn
-
2005
- 2005-09-05 ZA ZA200507100A patent/ZA200507100B/en unknown
- 2005-09-26 EC EC2005006038A patent/ECSP056038A/es unknown
- 2005-10-11 MA MA28549A patent/MA27727A1/fr unknown
- 2005-10-24 NO NO20054911A patent/NO20054911L/no not_active Application Discontinuation
- 2005-10-24 IS IS8087A patent/IS8087A/is unknown
-
2008
- 2008-10-30 AU AU2008237610A patent/AU2008237610A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IS8087A (is) | 2005-10-24 |
| EA200501527A1 (ru) | 2006-02-24 |
| EA009331B1 (ru) | 2007-12-28 |
| CN1768057A (zh) | 2006-05-03 |
| MXPA05010413A (es) | 2005-11-04 |
| BRPI0408752A (pt) | 2006-03-28 |
| ZA200507100B (en) | 2006-07-26 |
| NO20054911L (no) | 2005-10-24 |
| KR20050120670A (ko) | 2005-12-22 |
| AU2008237610A1 (en) | 2008-11-27 |
| US20070167494A1 (en) | 2007-07-19 |
| JP2006521340A (ja) | 2006-09-21 |
| AU2004224068A1 (en) | 2004-10-07 |
| WO2004085435A1 (en) | 2004-10-07 |
| EP1615918A1 (en) | 2006-01-18 |
| CA2520249A1 (en) | 2004-10-07 |
| MA27727A1 (fr) | 2006-01-02 |
| ECSP056038A (es) | 2006-01-27 |
| GB0307259D0 (en) | 2003-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8093387B2 (en) | Process of making crystalline type II aripiprazole | |
| JP7682868B2 (ja) | ジアステレオマー酒石酸エステルによるラセミ体の分割により２－シアノエチル（４ｓ）－４－（４－シアノ－２－メトキシフェニル）－５－エトキシ－２，８－ジメチル－１，４－ジヒドロ－１，６－ナフチリジン－３－カルボキシレートを調製する方法 | |
| US20050239772A1 (en) | Methods for preparation of olanzapine polymorphic form i | |
| FR2900655A1 (fr) | Forme alpha du mesylate d'imatinib et procede de production de celui-ci | |
| AU2008237610A1 (en) | Process for preparing a polymorph of rosiglitazone maleate | |
| JP2008094848A (ja) | 新規な型の４−［４−［４−（ヒドロキシジフェニルメチル）−１−ピペリジニル］−１−ヒドロキシブチル］−α，α−ジメチルベンゼン酢酸及びその塩酸塩 | |
| WO2007109799A2 (en) | Polymorphs of eszopiclone malate | |
| WO2008084494A1 (en) | Novel polymorphic forms of carvedilol dihydrogen phosphate and process for preparing the same | |
| CA2453751A1 (en) | Purification and crystalline forms of zapelon | |
| EP3656768A1 (en) | Beraprost-314d crystals and methods for preparation thereof | |
| AU2009336561A1 (en) | Stable R-(+)-lansoprazole amine salt and a process for preparing the same | |
| EP2197273B1 (en) | Process for preparing r-gossypol l-phenylalaninol dienamine | |
| EP2242758B1 (en) | Crystalline form of abacavir that is essentially free of solvent | |
| EP0531078B1 (en) | (R)-3-Methoxy-4- 1-methyl-5-(2-methyl-4,4,4-trifluorobutylcarbamoyl)indol-3-ylmethyl -N-(2-methylsulphonyl)benzamide in crystalline form | |
| KR101125123B1 (ko) | 높은 광학적 순도의 ｓ-(-)-암로디핀을 제조하는 방법 및 그 중간생성 화합물 | |
| KR102131107B1 (ko) | 3-아미노-피페리딘 화합물의 신규한 제조 방법 | |
| EP1858855B2 (en) | Process of making crystalline type ii aripiprazole | |
| JP4205130B2 (ja) | トレミフェン結晶化法 | |
| HRP20030246A2 (en) | Crystal forms of 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]piperazine hydrochloride | |
| CN109689620A (zh) | 拆分巴氯芬盐的方法 | |
| KR20220127965A (ko) | 리나글립틴의 안정한 결정형 b의 제조방법 | |
| US20060217408A1 (en) | Preparation of cabergoline | |
| KR20070088750A (ko) | 무수 아리피프라졸 제ｉｉ형의 제조 방법 | |
| CA2074058A1 (en) | Process to isolate carbacephem intermediates | |
| EP1140841A1 (fr) | Derives de 3-phenyl-2, 6-dioxopiperidin-3-yl propionamide et leur procede de preparation |